Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05547503Phase 1Completed

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Role: lead

NCT06649747Phase 2Not Yet Recruiting

Safety and Efficacy Study on AFA-281 for the Treatment of Low Back Pain

Role: lead

NCT06719908Phase 1Not Yet Recruiting

A Phase I Study of the Interaction of Alcohol With Oral AFA-281 in Healthy Volunteers

Role: lead

NCT06710431Phase 2Not Yet Recruiting

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Role: lead

All 4 trials loaded